Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency

Citations Over Time

Abstract

The history of stem cell gene therapy is strongly linked to the development of gene therapy for severe combined immunodeficiencies (SCID) and especially adenosine deaminase (ADA)-deficient SCID. Here we discuss the developments achieved in over two decades of clinical and laboratory research that led to the establishment of a protocol for the autologous transplant of retroviral vector-mediated gene-modified hematopoietic stem cells, which has proved to be both successful and, to date, safe. Patients in trials in three different countries have shown long-term immunological and metabolic correction. Nevertheless, improvements to the safety profile of viral vectors are underway and will undoubtedly reinforce the position of stem cell gene therapy as a treatment option for ADA-SCID.

Related Papers

• → Gene Therapy for Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency(2012)31 cited
• → Immunoreactive Adenosine Deaminase (ADA) in Cultured Fibroblasts from Patients with Combined Immunodeficiency Disease(1977)4 cited
• → Severe combined immunodeficiency due to adenosine deaminase deficiency(2020)4 cited
• → Gene therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID)(2009)1 cited
• → Orphan designation: Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene, Treatment of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency(2018)